| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Sanctuary Wellness Institute |
| URL | sanctuarywellnessinstitute.com/blog/does-trt-increase-lifespan (opens in a new tab) |
Specific Claim Evaluated
Testosterone therapy has neutral and in some cases favorable cardiovascular safety profiles in appropriate patients.
Primary Research Supporting or Contradicting the Claim
TRAVERSE found testosterone noninferior to placebo for major adverse cardiac events, with a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group (Lincoff et al., 2023).
Corrected Evidence-Based Interpretation
In men with confirmed hypogonadism and cardiovascular risk, testosterone did not increase major adverse cardiac events over about 2 years, but it increased atrial fibrillation, acute kidney injury and pulmonary embolism. No randomized trial has shown a cardiovascular or mortality benefit.
Rationale for Grade
The article states that testosterone is unlikely to be a life-extending drug and that the mortality association is not causal, which is appropriate. However, its cardiovascular summary omits the adverse signals from the same trial it cites, which a reader needs to judge the overall safety profile.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"